The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema
Sign Up to like & getrecommendations! Published in 2018 at "Ophthalmology and Therapy"
DOI: 10.1007/s40123-018-0155-5
Abstract: IntroductionTo determine anatomical, functional, and intraocular pressure (IOP) responses to diabetic macular edema (DME) treatments pre- and post-0.2 µg/day fluocinolone acetonide (FAc) implant administration compared with baseline and the preceding 3 years.MethodsThis was a retrospective, chart review,… read more here.
Keywords: post fac; treatment; fac implant; day ... See more keywords
Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema
Sign Up to like & getrecommendations! Published in 2017 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2017.1366663
Abstract: Abstract Objectives: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. Methods: The retrospective Iluvien… read more here.
Keywords: fac implant; fluocinolone acetonide; diabetic macular; macular edema ... See more keywords
Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Ophthalmology"
DOI: 10.1136/bjophthalmol-2020-315984
Abstract: Background The 0.2 µg/day fluocinolone acetonide (FAc) implant delivers continuous, low-dose, intravitreal corticosteroid for the treatment of diabetic macular oedema (DMO). This ongoing, 3-year, observational clinical trial provides long-term, ‘real-world’ safety results for the FAc… read more here.
Keywords: post fac; treatment; fac implant; year ... See more keywords
Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema
Sign Up to like & getrecommendations! Published in 2017 at "Ophthalmic Research"
DOI: 10.1159/000484091
Abstract: Purpose: To compare the functional and anatomical outcomes after a 0.2 µg/day fluocinolone acetonide (FAc) implant between vitrectomized and nonvitrectomized eyes with chronic diabetic macular edema (DME). Methods: This is a retrospective, comparative analysis of… read more here.
Keywords: fac implant; fluocinolone acetonide; group; day fac ... See more keywords
Alternative technique for the injection of fluocinolone acetonide (FAc) intravitreal implant (Iluvien ® ) in case of leakage of its injector
Sign Up to like & getrecommendations! Published in 2023 at "European Journal of Ophthalmology"
DOI: 10.1177/11206721221151136
Abstract: Purpose To show an alternative surgical technique for the introduction of the intravitreal fluocinolone acetonide (FAc) implant (Iluvien®) into the vitreous cavity using a 23-gauge (G) trocar if it is retained during its implantation in… read more here.
Keywords: fac implant; intravitreal; fluocinolone acetonide; acetonide fac ... See more keywords
Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME)
Sign Up to like & getrecommendations! Published in 2019 at "International Medical Case Reports Journal"
DOI: 10.2147/imcrj.s191171
Abstract: Objective: To assess long-term outcomes for effectiveness, safety, and treatment burden after injection of 0.2 µg/day fluocinolone acetonide [FAc] intravitreal implant (ILUVIEN®) in patients with persistent or recurrent diabetic macular edema (DME) and 6–18 months… read more here.
Keywords: macular edema; treatment; fac implant; treatment burden ... See more keywords